• Users Online: 683
  • Print this page
  • Email this page
This article has been cited by
1Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment
T.-F. Tsai
British Journal of Dermatology.2020;183(1)7
[DOI]
2Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis
T.-F. Tsai
British Journal of Dermatology.2021;184(5)791
[DOI]
3Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study*
K. Reich,A. Körber,U. Mrowietz,M. Sticherling,C. Sieder,J. Früh,T. Bachhuber
British Journal of Dermatology.2021;184(5)849
[DOI]
4Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
Cheng-Ying Chiang,Tsen-Fang Tsai
Dermatology and Therapy.2021;11(1)301
[DOI]
5Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
Tzong-Yun Ger,Yu-Huei Huang,Rosaline Chung-yee Hui,Tsen-Fang Tsai,Hsien-Yi Chiu
Therapeutic Advances in Chronic Disease.2019;10(1)204062231984375
[DOI]